Shahnoor Khan, MD
Psychiatry · Martinsburg, WVNPI 1346342458
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,795 of the $160,801 with a category attached, or 81.3%. 20 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 52.9% of the total. 2025 is the largest year on record at $38,720, 2.2 times the $17,244 reported in 2019. Among psychiatry clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 588 payments — averaging $273.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$85K
- AbbVie$73K
- Alkermes, Inc.$712
- Takeda Pharmaceuticals U.S.A., Inc.$547
- Teva Pharmaceuticals USA, Inc.$315
- Neurocrine Biosciences, Inc.$291
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$130,79581%
- Travel & lodging$20,59513%
- Food & beverage$9,2676%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 181 | $85,066 |
| AbbVie(2 entities) | 239 | $72,717 |
| Alkermes, Inc. | 32 | $712 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $547 |
| Teva Pharmaceuticals USA, Inc. | 14 | $315 |
| Neurocrine Biosciences, Inc. | 24 | $291 |
| Otsuka America Pharmaceutical, Inc. | 14 | $259 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $241 |
| Johnson & Johnson | 5 | $138 |
| Eisai Inc. | 3 | $112 |
| Shire North American Group Inc | 5 | $101 |
| Indivior Inc. | 5 | $78 |
| Lundbeck LLC | 4 | $66 |
| Philips North America LLC | 1 | $52 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Alfasigma USA, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$160,801 in reported general payments places this provider in the 95th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $39,661 |
| TrintellixVortioxetine Hydrobromide | 13 | $12,138 |
| Lurasidone Hcl | 25 | $11,695 |
| OzempicSemaglutide | 11 | $10,124 |
| Aripiprazole | 58 | $5,468 |
| Vilazodone Hcl | 37 | $3,320 |
| Prazosin Hcl | 68 | $2,756 |
| Clozapine | 25 | $2,700 |
| Quetiapine Fumarate | 143 | $2,269 |
| Ziprasidone Hcl | 19 | $2,121 |
| Triazolam | 44 | $1,755 |
| Duloxetine Hcl | 71 | $1,470 |
| Bupropion XlBupropion Hcl | 42 | $1,412 |
| Lamotrigine | 85 | $1,176 |
| Mirtazapine | 74 | $1,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $138 | $39,66112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $547 | $12,13813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Martinsburg
- Fezan RizviMartinsburg$8K
- Steven ChoiMartinsburg$4K
- Antonio Garcia MerinoMartinsburg$4K
- Ali AsgharMartinsburg$2K
- Joseph JurandMartinsburg$681
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.